Featured Research

from universities, journals, and other organizations

Obesity Gene: Mice Lacking FTO Gene Burn More Energy And Do Not Become Overweight

Date:
March 2, 2009
Source:
University of Cologne - Universitaet zu Koeln
Summary:
Mice which do not have FTO gene, burn more energy and do not become overweight. These findings verify the importance of the FTO gene for the regulation of body weight. The results of this research may lead to new ways of treating obesity.

Obesity has become an epidemic in many parts of the western hemisphere; over 30% of the population of Germany are overweight.

Scientists from the University of Cologne, in cooperation with scientists from the University of Düsseldorf, have been able to verify the relevance of a certain gene with regard to obesity for the first time.

In 2006, scientists discovered increased amounts of variations of the FTO genes were in overweight people. However, the relevance of this gene and its regular function remained unclear for a long time.

The team working for Prof. Dr. Jens Brüning, coordinator of the Cluster of Excellence "Cellular Stress Responses in Aging-Associated Diseases", CECAD Cologne, and Prof. Dr. Ulrich Rüther, University of Düsseldorf, have now been able to show that mice which do not have FTO gene, burn more energy and do not become overweight.

These findings verify the importance of the FTO gene for the regulation of body weight. The results of this research will become very important for the development of new ways of treating obesity.


Story Source:

The above story is based on materials provided by University of Cologne - Universitaet zu Koeln. Note: Materials may be edited for content and length.


Journal Reference:

  1. Fischer et al. Inactivation of the Fto gene protects from obesity. Nature, Feb 22, 2009; DOI: 10.1038/nature07848

Cite This Page:

University of Cologne - Universitaet zu Koeln. "Obesity Gene: Mice Lacking FTO Gene Burn More Energy And Do Not Become Overweight." ScienceDaily. ScienceDaily, 2 March 2009. <www.sciencedaily.com/releases/2009/02/090227072648.htm>.
University of Cologne - Universitaet zu Koeln. (2009, March 2). Obesity Gene: Mice Lacking FTO Gene Burn More Energy And Do Not Become Overweight. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/02/090227072648.htm
University of Cologne - Universitaet zu Koeln. "Obesity Gene: Mice Lacking FTO Gene Burn More Energy And Do Not Become Overweight." ScienceDaily. www.sciencedaily.com/releases/2009/02/090227072648.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins